Joanne Schindler, M.D., D.V.M., serves as Vice President, Clinical Development and Executive Medical Director with H3 Biomedicine. In this role, she is responsible for strategic leadership of H3’s clinical team, contributing medical and drug development expertise in the design of clinical development strategies and ensuring alignment with organizational goals. Dr. Schindler oversees development and execution of clinical research programs including the design, conduct, monitoring, interpretation of data, monitoring, and reporting of clinical trials.
Dr. Schindler brings over eighteen years of experience in oncology-focused research programs to her role at H3, including the development of antibody-drug conjugates, bispecific antibodies, molecularly-targeted small molecules, complex carbohydrates, antisense, and heavy metal drug candidates. She has been a key contributor to numerous Phase 1, 2 and pivotal studies in a variety of oncological indications including advanced solid tumors, liver, lung, breast, prostate, pancreas, lymphoma, leukemia, and multiple myeloma. Her drug development expertise includes regulatory and clinical development strategy, business plans, program management and oversight of clinical and preclinical research.
Prior to joining H3, Dr. Schindler was Clinical Program Lead – Hematology Oncology with Agios Pharmaceuticals. Previously, she held clinical development leadership roles with several companies including Constellation Pharmaceuticals, Inc., SynDevRx, Inc., ImmunoGen, Inc., Novartis, Fresenius Biotech, GlycoGenesys, Inc. and CareStat, Inc.
Dr. Schindler earned a B.A. from Brandeis University. She earned a D.V.M. from Tufts University School of Veterinary Medicine and, subsequently, and M.D. from the University of Connecticut School of Medicine. Dr. Schindler completed her post-doctoral training at the University of Massachusetts Medical Center, Department of Molecular Genetics and Microbiology.